JMP Securities Downgrades Chelsea Therapeutics (CHTP) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Needham & Company Downgrades Chelsea Therapeutics (CHTP) to Hold on Pending Takeover
May 9, 2014 10:17 AM EDTNeedham & Company downgraded Chelsea Therapeutics (NASDAQ: CHTP) from Buy to Hold after the company agreed to be acquired by Lundbeck at $6.44 per share (~$530M) with up to $1.50 per share (~$128M) in contingent payments.... More
Lundbeck to Acquire Chelsea Therapeutics (CHTP) in $658M Deal
May 8, 2014 7:56 AM EDTH. Lundbeck A/S (Lundbeck) and Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq: CHTP) announced that the companies have entered into a definitive agreement under which Lundbeck will acquire Chelsea.
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Chelsea, whereby Chelsea stockholders will be offered an upfront payment and contingent value rights (CVRs), representing a total potential consideration of up to USD 7.94 per share, or USD 658 million (approximately DKK 3.54 billion) on a fully diluted basis. The total potential consideration represents an attractive premium of... More
Lundbeck to Acquire Chelsea Therapeutics (CHTP) for $7.94/Share
May 8, 2014 7:49 AM EDTChelsea Therapeutics International Ltd. (NASDAQ: CHTP) to be acquired by Lundbeck for $7.94 per share.
... More